American Society for Microbiology, Journal of Virology, 24(96), 2022
DOI: 10.1128/jvi.01082-22
Full text: Download
The RV144 HIV-1 clinical vaccination trial showed modest protection against viral infection. Antibody responses to the V1V2 region of HIV-1 Env gp120 were correlated inversely with the risk of infection, and data from three other clinical vaccine trials suggested a similar signal.